Cargando…
Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry‐based cohort study
Cardiovascular disease (CVD) emerges as a major cause of death in patients with myelodysplastic syndrome (MDS), but predictors of fatal CVD and the effect of MDS‐specific treatments on CVD mortality remain largely unknown. In an analysis involving 831 patients with MDS with known causes of death, we...
Autores principales: | Liapis, Konstantinos, Vrachiolias, Georgios, Papadopoulos, Vasileios, Kourakli, Alexandra, Galanopoulos, Athanasios G., Papoutselis, Menelaos, Papageorgiou, Sotirios G., Diamantopoulos, Panagiotis T., Pappa, Vassiliki, Viniou, Nora‐Athina, Vassilakopoulos, Theodoros P., Hatzimichael, Eleftheria, Bouronikou, Eleni, Ximeri, Maria, Pontikoglou, Charalambos, Panayiotidis, Panayiotis, Karakatsanis, Stamatis, Vardi, Anna, Symeonidis, Argiris, Kotsianidis, Ioannis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176014/ https://www.ncbi.nlm.nih.gov/pubmed/35847690 http://dx.doi.org/10.1002/jha2.30 |
Ejemplares similares
-
Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
por: Liapis, Konstantinos, et al.
Publicado: (2021) -
Azacytidine Failure Revisited: an Appraisal Based on Real-Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)
por: Kotsianidis, Ioannis, et al.
Publicado: (2019) -
Real world data on the prognostic significance of monocytopenia in myelodysplastic syndrome
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2022) -
Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes
por: Papageorgiou, Sotirios G., et al.
Publicado: (2020) -
Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes
por: Mitroulis, Ioannis, et al.
Publicado: (2023)